Subscribe
shutterstock_1587802498_nitpicker
nitpicker / Shutterstock.com
29 June 2021AmericasMuireann Bolger

Flatwing fails to shift attorney fees to Pfizer unit, Anacor

Generic drug maker Flatwing Pharmaceuticals has lost its bid to offset nearly $690,000 in fees and expenses to Pfizer unit Anacor Pharmaceuticals after a US federal judge ruled that the “circumstances were not exceptional” enough to warrant the shift.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Fed Circuit affirms cancellation of Anacor antifungal patents
1 September 2020   Anacor Pharmaceuticals has unsuccessfully challenged the invalidation of four patents covering Kerydin, an antifungal treatment for nails.
Americas
Pfizer buys Anacor for $5.2bn
18 May 2016   Pfizer has announced that it will be buying Anacor Pharmaceuticals for $5.2 billion, which will lead to it adding an experimental treatment for eczema, called Crisaborole, to its portfolio.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Americas
Fed Circuit affirms cancellation of Anacor antifungal patents
1 September 2020   Anacor Pharmaceuticals has unsuccessfully challenged the invalidation of four patents covering Kerydin, an antifungal treatment for nails.
Americas
Pfizer buys Anacor for $5.2bn
18 May 2016   Pfizer has announced that it will be buying Anacor Pharmaceuticals for $5.2 billion, which will lead to it adding an experimental treatment for eczema, called Crisaborole, to its portfolio.

More on this story

Americas
Fed Circuit affirms cancellation of Anacor antifungal patents
1 September 2020   Anacor Pharmaceuticals has unsuccessfully challenged the invalidation of four patents covering Kerydin, an antifungal treatment for nails.
Americas
Pfizer buys Anacor for $5.2bn
18 May 2016   Pfizer has announced that it will be buying Anacor Pharmaceuticals for $5.2 billion, which will lead to it adding an experimental treatment for eczema, called Crisaborole, to its portfolio.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB